Celyad Oncology 
Welcome,         Profile    Billing    Logout  
 6 Products   8 Diseases  6 Products   8 Trials   511 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CYAD-01 / Celdara Medical, Celyad Oncology
2018-000205-22: Research study aiming at investigating the potential safety of multiple administrations of NKR-2 after chemotherapy treatment targeting T-cells in patients with acute myeloid leukemia. The NKR-2 treatment is based on patient's own T-cells that will be collected and modified before being injected to generate anti-tumor responses.

Not yet recruiting
1/2
17
Europe
NKR-2, NKR-2, Concentrate for solution for infusion
Celyad Onclogy SA, Celyad Oncology SA
NKR-2 has the potential to treat many distinct tumor-types. This trial will focus on Relapsed and/or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)., NKR-2 is indicated for the treatment of blood cancer., Diseases [C] - Cancer [C04]
 
 
CYAD-101 / Celyad Oncology
alloSHRINK, NCT03692429: - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Checkmark From alloSHRINK trial for mCRC
Jul 2019 - Jul 2019: From alloSHRINK trial for mCRC
Hourglass Jul 2017 - Dec 2017 : Initiation of allogeneic P1 trial in cancer (unspecified tumor type)
: Topline data from alloSHRINK trial in colorectal
: Topline data from alloSHRINK trial in colorectal
More
Recruiting
1
49
Europe, US
CYAD-101, FOLFOX, FOLFIRI
Celyad Oncology SA
Unresectable Metastatic Colorectal Cancer
11/21
02/36
KEYNOTE-B79, NCT04991948: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
1
34
Europe, US
CYAD-101, FOLFOX, Pembrolizumab
Celyad Oncology SA, Merck Sharp & Dohme Corp.
Unresectable Metastatic Colorectal Cancer
08/23
05/38
CYAD-02 / Celyad Oncology
CYCLE-1, NCT04167696: Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting
1
27
Europe, US
CYAD-02, ENDOXAN, cyclophosphamide, Fludara, fludarabine
Celyad Oncology SA
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/21
02/35
CYAD-211 / Celyad Oncology
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
18
Europe, US
CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine
Celyad Oncology SA
Relapse/Refractory Multiple Myeloma
12/22
02/37
CYAD-231 / Celyad Oncology
No trials found
CYAD-103 / Celyad Oncology
No trials found
CYAD-203 / Celyad Oncology
No trials found
Undisclosed GPC3 CAR-T / Celyad Oncology
No trials found
CD19/NKG2DL CAR-T Therapeutic / Celyad Oncology
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CYAD-01 / Celdara Medical, Celyad Oncology
2018-000205-22: Research study aiming at investigating the potential safety of multiple administrations of NKR-2 after chemotherapy treatment targeting T-cells in patients with acute myeloid leukemia. The NKR-2 treatment is based on patient's own T-cells that will be collected and modified before being injected to generate anti-tumor responses.

Not yet recruiting
1/2
17
Europe
NKR-2, NKR-2, Concentrate for solution for infusion
Celyad Onclogy SA, Celyad Oncology SA
NKR-2 has the potential to treat many distinct tumor-types. This trial will focus on Relapsed and/or refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)., NKR-2 is indicated for the treatment of blood cancer., Diseases [C] - Cancer [C04]
 
 
CYAD-101 / Celyad Oncology
alloSHRINK, NCT03692429: - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Checkmark From alloSHRINK trial for mCRC
Jul 2019 - Jul 2019: From alloSHRINK trial for mCRC
Hourglass Jul 2017 - Dec 2017 : Initiation of allogeneic P1 trial in cancer (unspecified tumor type)
: Topline data from alloSHRINK trial in colorectal
: Topline data from alloSHRINK trial in colorectal
More
Recruiting
1
49
Europe, US
CYAD-101, FOLFOX, FOLFIRI
Celyad Oncology SA
Unresectable Metastatic Colorectal Cancer
11/21
02/36
KEYNOTE-B79, NCT04991948: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
1
34
Europe, US
CYAD-101, FOLFOX, Pembrolizumab
Celyad Oncology SA, Merck Sharp & Dohme Corp.
Unresectable Metastatic Colorectal Cancer
08/23
05/38
CYAD-02 / Celyad Oncology
CYCLE-1, NCT04167696: Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting
1
27
Europe, US
CYAD-02, ENDOXAN, cyclophosphamide, Fludara, fludarabine
Celyad Oncology SA
Acute Myeloid Leukemia, Myelodysplastic Syndrome
12/21
02/35
CYAD-211 / Celyad Oncology
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
18
Europe, US
CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine
Celyad Oncology SA
Relapse/Refractory Multiple Myeloma
12/22
02/37
CYAD-231 / Celyad Oncology
No trials found
CYAD-103 / Celyad Oncology
No trials found
CYAD-203 / Celyad Oncology
No trials found
Undisclosed GPC3 CAR-T / Celyad Oncology
No trials found
CD19/NKG2DL CAR-T Therapeutic / Celyad Oncology
No trials found

Download Options